Reading this on a mobile device? Try our optimized mobile version here:

December 27, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
  • NIAID to test flu drug candidate
    The National Institute of Allergy and Infectious Diseases and Sarepta Therapeutics entered into a clinical trial agreement centered on the latter's AVI-7100, an investigational drug for influenza viruses. NIAID will conduct an early-stage trial to assess the drug's safety, tolerability and pharmacokinetics in healthy volunteers. Sarepta will use the trial data to support the development of AVI-7100. Pharmaceutical Business Review Online (12/24) LinkedInFacebookTwitterEmail this Story
Quality and Process Improvement Solutions are Just a Click Away
AABB Consulting Services can help you meet the requirements of any accrediting organization. Guidance is also available for: implementation plans, process flow, software issues, computer validation, compliance audits, vendor audits and custom projects. For more information, visit our web site or email

  Science & Health 
  • Drug shortages lead to higher relapse rates in Hodgkin lymphoma
    Children and young adults with Hodgkin lymphoma who were treated with a substitute drug regimen during a shortage of mechlorethamine had higher relapse rates than those given standard care, according to an analysis involving 221 patients. The findings appear in the New England Journal of Medicine. USA Today (12/27) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • HHS seeks feedback on HIT safety plan
    HHS is seeking public comments as it unveils a safety plan from the Office of the National Coordinator for Health IT to address the possibility that HIT contributes to medical errors. The action program includes strategies and objectives to encourage stakeholders to better organize their plans to boost the safety of HIT. The deadline for comments is Feb. 4. Health Data Management (12/24) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Expanded FDA approval is sought for anemia drug
    AMAG Pharmaceuticals filed a supplemental new drug application with the FDA seeking approval to market injectable Feraheme, or ferumoxytol, to patients with iron deficiency anemia who don't respond to or can't take oral iron therapy. The filing was based on the results of an international, late-stage program with more than 1,400 participants. RTT News (12/24) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • Mexico changes donor policy regarding MSM
    Mexico on Tuesday implemented regulations that do not screen blood donors based on sexual orientation. Under the new law, men who have sex with men and who do not have HIV or hepatitis and who practice safe sex will be allowed to donate. Gay Star News (12/27) LinkedInFacebookTwitterEmail this Story
  • FDA issues guidance to expedite drug development
    The FDA has released a draft guidance document designed to help drug companies speed development. The 42-page guidance outlines "enrichment strategies" meant to improve the efficiency of drug trials such as excluding patients unlikely to demonstrate clinical benefit. "These are potentially powerful strategies for the pharmaceutical industry because appropriate use of enrichment could result in smaller studies, shortened drug development times, and lower development costs," wrote Dr. Bob Temple of the FDA. MedPage Today (free registration) (12/26) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Hospitals encouraged to inform AABB of their participation in NHSN Hemovigilance Module
    Hospitals are encouraged to inform AABB of their participation in the Hemovigilance Module of the CDC's National Healthcare Safety Network. The CDC does not identify participating institutions due to the confidentiality rules to which it must adhere. Hospitals that identify themselves to AABB will be invited to join AABB's Hemovigilance Module Transfusion Safety Group. Staff of AABB's Patient and Donor Safety Center, working with additional experts, will analyze the group's hemovigilance data with the goal of developing interventions that will improve patient safety at the individual institutions and nationwide. Contact AABB's Patient and Donor Safety Center at (301) 215-6588 or by e-mail. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Laboratory ManagerCreative Testing SolutionsUS - IL - Chicago
Quality SpecialistBlood Systems, Inc.US - NV - Las Vegas
Laboratory SupervisorCreative Testing SolutionsUS - IL - Chicago
Performance Improvement ConsultantBlood Systems, Inc.US - AZ - Scottsdale
LABORATORY MANAGERUnited Blood ServicesUS - NV - Las Vegas
QA SpecialistSan Diego Blood BankUS - CA
Reference TechnologistLifeStreamUS - CA - San Bernardino
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

People who lean on logic and philosophy and rational exposition end by starving the best part of the mind."
--William Butler Yeats,
Irish poet and playwright

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information